Haematopoietic graft engineering

Annals of the Academy of Medicine Singapore

Volumn 33, Issue 5, 2004, Pages 551-558

  Hwang, William Ying Khee ^a,b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b Singapore Health Services   (Singapore)

Author keywords

Graft engineering; Graft versus host disease; Graft versus tumour

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; 4 HYDROXYCYCLOPHOSPHAMIDE; ACICLOVIR; ADENOVIRUS VECTOR; AMIFOSTINE; AMINOLEVULINIC ACID; CD133 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD52 ANTIGEN; CD8 ANTIGEN; COMPLEMENT; CYCLOPHOSPHAMIDE; CYTOSINE DEAMINASE; FAS ANTIGEN; FAS LIGAND; GRANZYME A; INTERLEUKIN 2 RECEPTOR; LECTIN; MAFOSFAMIDE; MONOCLONAL ANTIBODY; PERFORIN; SAPORIN; THYMIDINE KINASE; TUMOR ANTIGEN;

APLASTIC ANEMIA; CENTRIFUGATION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENGINEERING; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; GENE TRANSFER; GOOD MANUFACTURING PRACTICE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX VIRUS; HUMAN; HYPERTHERMIC THERAPY; LYMPHOCYTE DEPLETION; MUCOSA INFLAMMATION; NONHUMAN; PHOTODYNAMIC THERAPY; RELAPSE; REVIEW; T LYMPHOCYTE; THALASSEMIA;

EID: 10344240882     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Odom LF, August CS, Githens JH, Humbert JR, Morse H, Peakman D, et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man? Lancet 1978;2:537-40.
2. Santos GW, Hess AD, Vogelsang GB. Graft-versus-host reactions and disease. Immunol Rev 1985;88:169-92.
3. Martin PJ, Hansen JA, Storb R, Thomas ED. Human marrow transplantation: An immunological perspective. Adv Immunol 1987;40:379-438.
4. Koh MB, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from hematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant 1999;23:1071-9.
5. Reisner Y, Kapoor N, OReilly RJ, Good RA. Allogeneic bone marrow transplantation using stem cells fractionated by lectins: VI. In vitro analysis of human and monkey bone marrow cells fractionated by sheep red blood cells and soybean agglutinin. Lancet 1980;2:1320-4.
6. O'Reilly RJ, Brochstein J, Collins N, Keever C, Kapoor N, Kirkpatrick D, et al. Evaluation of HLA-haplotype disparate parental marrow grafts depleted of T lymphocytes by differential agglutination with a soybean lectin and E-rosette depletion for the treatment of severe combined immunodeficiency. Vox Sang 1986;51(Suppl 2):81-6.
7. Fillipovich AH, McGlave PB, Ramsay NK, Goldstein G, Warheustein PI. Treatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone marrow transplantation. Lancet 1982;1:1266-9.
8. Kersey JH, Vallera D, Ramsey N, Fillipovich A, Youle R, Neville D, et al. Monoclonal antibodies and immunotoxins in bone marrow transplantation: purging marrow of ALL or GVHD cells with preservation of stem cells. Hematol Blood Transfus 1985;29:34-8.
9. Heit W, Bunjes D, Wiesneth M, Schmeiser T, Arnold R, Hale G, et al. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br J Haematol 1986;64:479-86.
10. Soukhanov AH, Jost DA, Ellis K, Severynse M, editors. The American Heritage Dictionary of the English Language. 3rd ed. Houghton Mifflin Company. Boston, MA 1996.
11. De Witte T, Hoogenhout J, de Pauw B, Holdrinet R, Janssen J, Wessels J, et al. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogenic marrow transplantation. Blood 1986;67:1302-8.
12. Wagner JE, Santos GW, Noga SJ, Rowley SD, Davis J, Vogelsang GB, et al. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. Blood 1990;75:1370-7.
13. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, et al. Antileukemia effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300:1068-3.
14. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018-23.
15. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041-50.
16. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
17. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-24.
18. Nagler A, Condiotti R, Nabet C, Naparstek E, Or R, Samuel S, et al. Selective CD4+ T-cell depletion does not prevent graft-versus-host disease. Transplantation 1998;66:138-41.
19. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995;86:4337-43.
20. Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, et al. Toxicity and efficacy of defined doses of CD4 (+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998;91:3671-80.
21. Martin PJ, Rowley SD, Anasetti C, Chauncey TR, Gooley T, Petersdorf EW, et al. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood 1999;94:2192-9.
22. Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, et al. Differential use of Fas ligand and perform cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 2001;97:2886-95.
23. Tsukada N, Kobata T, Aizawa Y, Yagita H, Okumura K. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 1999;93:2738-47.
24. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996;183:2645-56.
25. Pan L, Teshima T, Hill GR, Bungard D, Brinson YS, Reddy VS, et al. Granulocyte colony stimulating factor mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effect through a perforin-dependent pathway while preventing graft-versus-host disease. Blood 1999:93:4071-8.
26. Hsieh MH, Korngold R. Differential use of FasL and perforin mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. Blood 2000;96:1047-55.
27. Van den Brink MR, Burakoff SJ. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2002;2:273-81.
28. Davidson DE, Grenan MM, Sweeney TR. Biological characteristics of some improved radioprotectors. In: Brady LW. editor. Radiation Sensitizers. New York: Masson, 1980:309-20.
29. Wasserman TH, Phillips TL, Ross G, Kane LJ. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 1981:4:3-6.
30. Douay L, Hu C, Giarratana MC, Gorin NC. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. Eur J Cancer 1995;31A (Suppl 1):S14-6.
31. Calabro-Jones PM, Fahey RC, Smoluk GD, Ward JF. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 1985;47:23-7.
32. Cagnoni PJ, Jones RB, Bearman SI, Ross M, Hami L, Franklin WA, et al. Use of amifostine in bone marrow purging. Semin Oncol 1996;23:44-8.
33. Hwang WYK, Koh LP, Ng HJ, Tan PHC, Chuah CTH, Fook CTH, et al. A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2004 (in press).
34. Krolick KA, Uhr JW, Vitetta ES. Selective killing of leukemia cells by antibody-toxin conjugates: implications for autologous bone marrow transplantation. Nature 1982:295:604-5.
35. Barbieri L, Dinota A, Gobbi M, Tazzari PL, Rizzi S, Bontadini A, et al. Immunotoxins containing saporin 6 and monoclonal antibodies recognizing plasma cell associated antigens: effects on target cells and on normal myeloid precursors (CFU-GM). Eur J Haematol 1989;42:238-45.
36. Vrendenburgh JJ, Simpson W, Memoli VA, Ball ED. Reactivity of anti-CD15 monoclonal antibody PM-81 with breast cancer and elimination of breast cancer cells from human bone marrow by PM-81 and immunomagnetic beads. Cancer Res 1991:51:2451-5.
37. Civin CI, Trischmann T, Kadan NS, Davis J, Noga S, Cohen K, et al. Highly purified CD34+ cells reconstitute hematopoiesis. J Clin Oncol 1996:14:2224-33.
38. Nimgaonkar M, Kemp A, Lancia J, Ball ED. A combination of CD34 selection and complement-mediated immunopurging (anti-CD15 monoclonal antibody) eliminates tumor cells while sparing normal progenitor cells. J Hematother 1996:5:39-48.
39. Bertolini F, Thomas T, Battaglia M, Gibelli N, Pedrazzoli P, Robustelli della Cuna G. A new "two step" procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation. Bone Marrow Transplant 1997;19:615-9.
40. Garcia-Castro J, Rio P, Lillo R, Garcia-Sanchez F, Segovia JC, Bueren JA. Purging of leukemia-contaminated bone marrow grafts using suicide adenoviral vectors: an in vivo murine experimental model. Gene Ther 2003;10:1328-35.
41. Wierenga PK, Setroikromo R, Kamps G, Kampinga HH, Vellenga E. Differences in heat sensitivity between normal and acute myeloid leukemic stem cells: feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts. Exp Hematol 2003;31:421-7.
42. Hrkal Z, Grebenova D, Cajthamlova H, Soucek J, Bartosova J, Fuchs O, et al. [Use of photodynamic therapy for elimination of residual leukemic cells in autologous transplants of hematopoietic progenitor cells]. Cas Lek Cesk 2002;141(Suppl):41-6.
43. Hwang W, Gullo C, Au M, Teoh G, Guo E, Lim TY, et al. Induction of cytolytic natural killer cells and tumour rejection in multiple myeloma using ultraviolet light irradiated tumour cells for lymphocyte priming. In: American Society of Haematology 2003 Annual Meeting Proceedings. Blood 2003;102:Abstract #5200.
44. Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves CJ. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci U S A 1990;87:3584-8.
45. Breems DA, Blokland EA, Neben S, Ploemacher RE. Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia 1994;8:1095-104.
46. McNiece IK, Bertoncello I, Kriegler AB, Quesenberry PJ, Zsebo KM. Colony-forming cells with high proliferative potential (HPP-CFC). In: Murphy MJ Jr, editor. Concise Reviews in Clinical and Experimental Hematology. Dayton: AlphaMed Press, 1992:267-77.
47. Encabo A, Mateu E, Carbonell-Uberos F, Minana MD. CD34+CD38- is a good predictive marker of cloning ability and expansion potential of CD34+ cord blood cells. Transfusion 2003;43:383-9.
48. Kobari L, Giarratana MC, Pflumio F, Izac B, Coulombel L, Douay L. CD133+ cell selection is an alternative to CD34+ cell selection for ex vivo expansion of hematopoietic stem cells. J Hematother Stem Cell Res 2001;10:273-81.
49. Forraz N, Pettengell R, McGuckin CP. Characterization of a lineage-negative stem-progenitor cell population optimized for ex vivo expansion and enriched for LTC-IC. Stem Cells 2004;22:100-8.
50. Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995;1:1268-73.
51. Reisner Y, Bachar-Lustig E, Li HW, Aversa F, Velardi A, Martelli MF. The role of megadose CD34+ progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation. Ann N Y Acad Sci 1999;872:336-48.
52. Beelen DW, Peceny R, Elmaagacli A, Ottinger H, Kummer G, Opalka B, et al. Transplantation of highly purified HLA-identical sibling donor peripheral blood CD34+ cells without prophylactic post-transplant immunosuppression in adult patients with first chronic phase chronic myeloid leukemia: results of a phase II study. Bone Marrow Transplant 2000;26:823-9.
53. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997;337:373-81.
54. Purdy MH, Hogan CJ, Hami L, McNiece I, Franklin W, Jones RB, et al. Large volume expansion of CD34-positive hematopoietic progenitor cells for transplantation. J Hematother 1995;4:515-25.
55. Jaroscak J, Goltry K, Smith A, Waters-Pick B, Martin PL, Driscoll TA, et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. Blood 2003;101:5061-7.
56. Kobari L, Giarratana MC, Poloni A, Firat H, Labopin M, Gorin NC, et al. Flt 3 ligand, MGDF, Epo and G-CSF enhance ex vivo expansion of hematopoietic cell compartments in the presence of SCF, IL-3 and IL-6. Bone Marrow Transplant 1998;21:759-67.
57. Zhang Y, He J, Jiang XX, Liu G, Liu YL, Tang PH, et al. [Human placenta derived adherent cells support in vitro expansion of umbilical cord blood CD34(+) cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2003;11:560-4.
58. Yoo ES, Lee KE, Seo JW, Yoo EH, Lee MA, Im SA, et al. Adherent cells generated during long-term culture of human umbilical cord blood CD34+ cells have characteristics of endothelial cells and beneficial effect on cord blood ex vivo expansion. Stem Cells 2003;21:228-35.
59. Verfaillie CM. Direct contact between human primitive hematopoietic progenitors and bone marrow stroma is not required for long-term in vitro hematopoiesis. Blood 1992;79:2821-6.
60. Hwang YK, Sun L, Teoh G, Aw SE, Sandmeier B, Tan P. Enrichment of CD34 positive cells in co-cultures of hematopoietic progenitor cells on autologous long term bone marrow stromal cells using S5 anti-CD44 monoclonal antibody. In: American Society of Haematology 2002 Annual Meeting Proceedings. Blood 2002;100(Suppl 2):Abstract #5260.
61. Briddell RA, Kern BP, Zilm KL, Stoney GB, McNiece IK. Purification of CD34+ cells is essential for optimal ex vivo expansion of umbilical cord blood cells. J Hematother 1997;6:145-50.
62. Shieh JH, Chen YF, Briddell R, Stoney G, McNiece I. High purity of blast cells in CD34 selected populations are essential for optimal ex vivo expansion of human GM-CFC [abstract]. Exp Hematol 1994;22:756a.
63. Shaw PH, Gilligan D, Wang XM, Thall PF, Corey SJ. Ex vivo expansion of megakaryocyte precursors from umbilical cord blood CD34 cells in a closed liquid culture system. Biol Blood Marrow Transplant 2003;9:151-6.
64. Stoney GB, Briddell RA, Kern BP, Zilm KL, McNiece IK. Clinical scale ex vivo expansion of myeloid progenitor cells and megakaryocytes under GMP conditions [abstract]. Exp Hematol 1996;24:1043a.
65. Kim HS, Lim JB, Min YH, Lee ST, Lyu CJ, Kim ES, et al. Ex vivo expansion of human umbilical cord blood CD34+ cells in a collagen bead-containing 3-dimensional culture system. Int J Hematol 2003;78:126-32.
66. Koller MR, Emerson SG, Palsson BO. Large-scale expansion of human stem and progenitor cells from bone marrow mononuclear cells in continuous perfusion cultures. Blood 1993;82:378-84.
67. Sardonini CA, Wu YJ. Expansion and differentiation of human hematopoietic cells from static cultures through small-scale bioreactors. Biotechnol Prog 1993;9:131-7.
68. Muench MO, Firpo MT, Moore MAS. Bone marrow transplantation with interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood 1993;81:3463-73.
69. Andrews RG, Briddell RA, Gough M, McNiece IK. Expansion of G-CSF mobilized CD34+ peripheral blood cells (PBC) for 10 days in G-CSF, MGDF and SCF prior to transplantation decreased posttransplant neutropenia in baboons [abstract]. Blood 1997;90(Suppl 1):92a.
70. McNiece I, Hami L, Jones R, et al. Transplantation of ex vivo expanded PBPC after high dose chemotherapy results in decreased neutropenia [abstract]. Blood 1998;92(Suppl 1):126a.
71. Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003;101:1637-44.
72. Miller JS, Verfaillie C, McGlave P. The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture. Blood 1992;80:2182-7.
73. Verneris MR, Ito M, Baker J,Arshi A, Negrin RS, Shizuru JA. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001;7:532-42.
74. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
75. Bernhard H, Disis ML, Heimfeld S, Hand S, Gralow JR, Cheever MA. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 1995;55:1099-104.
76. Henderson RA, Nimgaonkar MT, Watkins SC, Robbins PD, Ball ED, Finn OJ. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 1996;56:3763-70.
77. Chilton PM, Huang Y, Ildstad ST. Bone marrow cell graft engineering: from bench to bedside. Leuk Lymphoma 2001;41:19-34.
78. Herve P. Donor-derived hematopoietic stem cells in organ transplantation: technical aspects and hurdles yet to be cleared. Transplantation 2003;75(9 Suppl):55S-7.
79. Thompson L. Correcting the Code: Inventing the Genetic Cure for the Human Body. New York: Simon and Schuster, 1994.
80. Hoogerbrugge PM, van Beusechem VW, Fischer A, Debree M, le Deist F, Perignon JL, et al. Bone marrow gene transfer in three patients with adenosine deaminase deficlency. Gene Ther 1996;3:179-83.
81. Dunbar CE, Kohn DB, Schiffmann R, Barton NW, Nolta JA, Esplin JA, et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther 1998;9:2629-40.
82. Malech HL, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 1997;94:12133-8.
83. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1989;320:1418-9.
84. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-23.
85. Webb IJ, Coral FS, Andersen JW, Elias AD, Finberg RW, Nadler LM, et al. Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering. Transfusion 1996;36:782-8.
86. Current Good Manufacturing Practice for Blood and Blood Components. Code of Federal Regulations Title 21, Part 606, 2000.
87. Warkentin PI, editor. Standards for hematopoietic progenitor cell collection, processing and transplantation, 2nd ed. Omaha, NE: Foundation for the Accreditation of Cellular Therapy, 2002.
88. American Association of Blood Banks, America's Blood Centers, American Red Cross. Circular of information for the use of human blood and blood components. Bethesda, MD: American Association of Blood Banks, 2002.
89. Warkentin PI, Nick L, Shpall EJ. FAHCT accreditation: common deficiencies during on-site inspections. Cytotherapy 2000;2:213-20.
90. US Food and Drug Administration. A proposed approach to the regulation of cellular and tissue-based products. Fed Reg 1997;62:9721.
91. US Food and Drug Administration. Guidance for Human Somatic Cell and Gene Therapy, Guidance for Industry, Center for Biologics Evaluation and Research, March 1998.